Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice
Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the syn...
Saved in:
Published in | The Journal of pharmacology and experimental therapeutics Vol. 358; no. 2; pp. 334 - 341 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The American Society for Pharmacology and Experimental Therapeutics
01.08.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function. |
---|---|
AbstractList | Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function. Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ 9 -tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ -opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the B max value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function. Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function. |
Author | Chopda, Girish R Thakur, Ganesh A Gatley, S John Makriyannis, Alexandros Paronis, Carol A Parge, Viraj |
Author_xml | – sequence: 1 givenname: Girish R surname: Chopda fullname: Chopda, Girish R email: cparonis@mclean.harvard.edu, girishchopda@yahoo.com organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) cparonis@mclean.harvard.edu girishchopda@yahoo.com – sequence: 2 givenname: Viraj surname: Parge fullname: Parge, Viraj organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) – sequence: 3 givenname: Ganesh A surname: Thakur fullname: Thakur, Ganesh A organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) – sequence: 4 givenname: S John surname: Gatley fullname: Gatley, S John organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) – sequence: 5 givenname: Alexandros surname: Makriyannis fullname: Makriyannis, Alexandros organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) – sequence: 6 givenname: Carol A surname: Paronis fullname: Paronis, Carol A email: cparonis@mclean.harvard.edu, girishchopda@yahoo.com organization: Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (G.R.C., V.P., G.A.T., S.J.G., A.M., C.A.P.); Dicerna Pharmaceuticals, Cambridge, Massachusetts (G.R.C.); Momenta Pharmaceuticals, Cambridge, Massachusetts (V.P.); Preclinical Pharmacology Program, McLean Hospital, Belmont, Massachusetts (C.A.P.) cparonis@mclean.harvard.edu girishchopda@yahoo.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27231154$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkMtKBDEQRYMoOj7W7iRLN615d2cjSPsYQXEzrptMUtFIT9J2MoK_5kf4TY44iq7qQt06l1u7aDOmCAgdUnJCKROnzwOUlVInjDPK2QaaUMloRSjhm2hCCGMVl0ruoN2cnwmhQii-jXZYzTilUkzQMEs9jCZawCXh8gT4IixHKMHiS-_BloyTx62J0cxDTMFlbKLD7Zhyrv7dGvzxXt0PYeXB548phlxwiHg2bavZCKaAw3fBwj7a8qbPcLCee-jh6nLWTqvb--ub9vy2GphSpbKcKKZlTYXzoua00U5pq7llvgEiCeWNE1pRCzWXzNeNk_WqtVdMSD8Xju-hs2_usJwvwFmIZTR9N4xhYca3LpnQ_d_E8NQ9ptdOaKmJZivA8Rowppcl5NItQrbQ9yZCWuaONkQ0Uur6y3r0N-s35OfN_BMAEYGw |
ContentType | Journal Article |
Copyright | Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics. Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics 2016 |
Copyright_xml | – notice: Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics. – notice: Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics 2016 |
DBID | CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1124/jpet.116.232132 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Tolerance to Cannabinoid Diuresis |
EISSN | 1521-0103 |
EndPage | 341 |
ExternalDocumentID | 27231154 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NIDA NIH HHS grantid: R21 DA035411 |
GroupedDBID | --- -~X .55 .GJ 0R~ 18M 2WC 3O- 4.4 53G 5GY 5RE 5VS 8WZ A6W AAJMC AAYOK ABCQX ABIVO ABJNI ABOCM ABSQV ACGFO ACGFS ACNCT ADBBV ADCOW ADIYS AENEX AERNN AFFNX AFHIN AFOSN AGFXO AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P F9R GX1 H13 HZ~ INIJC KQ8 L7B LSO MJL MVM NPM O9- OHT OK1 P2P R.V R0Z RHF RHI RPT TR2 UQL VH1 W2D W8F WH7 WOQ X7M YBU YHG YQT ZGI ZXP 7X8 5PM |
ID | FETCH-LOGICAL-p266t-c306295714df473189d69c93c2f8e050138d4961ce7352f78d57010f6245fb4d3 |
ISSN | 0022-3565 |
IngestDate | Tue Sep 17 20:45:01 EDT 2024 Sat Oct 26 01:26:18 EDT 2024 Sat Sep 28 08:49:01 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
License | Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p266t-c306295714df473189d69c93c2f8e050138d4961ce7352f78d57010f6245fb4d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 27231154 |
PQID | 1804855972 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4959092 proquest_miscellaneous_1804855972 pubmed_primary_27231154 |
PublicationCentury | 2000 |
PublicationDate | 2016-08-00 20160801 |
PublicationDateYYYYMMDD | 2016-08-01 |
PublicationDate_xml | – month: 08 year: 2016 text: 2016-08-00 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bethesda, MD |
PublicationTitle | The Journal of pharmacology and experimental therapeutics |
PublicationTitleAlternate | J Pharmacol Exp Ther |
PublicationYear | 2016 |
Publisher | The American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: The American Society for Pharmacology and Experimental Therapeutics |
References | 21246187 - Psychopharmacology (Berl). 2011 Jun;215(4):665-75 20354680 - Psychopharmacology (Berl). 2010 Jun;210(2):275-84 12943018 - J Abnorm Psychol. 2003 Aug;112(3):393-402 1992016 - J Neurosci. 1991 Feb;11(2):563-83 1666911 - Pharmacol Biochem Behav. 1991 Nov;40(3):471-8 2991502 - J Pharmacol Exp Ther. 1985 Aug;234(2):463-9 9389377 - Eur J Pharmacol. 1997 Oct 15;337(1):27-34 20664173 - J Clin Invest. 2010 Aug;120(8):2953-66 24099963 - Eur J Pharmacol. 2013 Dec 5;721(1-3):64-9 7996450 - J Pharmacol Exp Ther. 1994 Dec;271(3):1383-90 13621144 - J Ment Sci. 1958 Oct;104(437):972-99 8930163 - J Pharmacol Exp Ther. 1996 Nov;279(2):608-16 11826143 - J Neurosci. 2002 Feb 1;22(3):1146-54 16292318 - Neuropsychopharmacology. 2006 Sep;31(9):1957-66 26361728 - Pharmacol Res. 2015 Dec;102:22-32 16760363 - Mol Pharmacol. 2006 Sep;70(3):986-96 9918548 - J Pharmacol Exp Ther. 1999 Feb;288(2):478-83 8138952 - J Pharmacol Exp Ther. 1994 Mar;268(3):1381-7 23536317 - J Pharmacol Exp Ther. 2013 Jun;345(3):354-62 10087079 - J Neurosci. 1999 Apr 1;19(7):2658-64 22264443 - Biol Psychiatry. 2012 Apr 15;71(8):714-24 12235230 - J Pharmacol Exp Ther. 2002 Oct;303(1):36-44 10582605 - J Neurochem. 1999 Dec;73(6):2447-59 19284549 - Mol Pain. 2009 Mar 10;5:11 9422389 - J Neurochem. 1998 Jan;70(1):417-23 10940538 - Drug Alcohol Depend. 2000 Aug 1;60(2):113-9 17953671 - J Neurochem. 2007 Dec;103(6):2629-39 22718500 - J Pharmacol Exp Ther. 2012 Sep;342(3):843-9 23075707 - Behav Pharmacol. 2012 Dec;23(8):802-5 17967938 - J Pharmacol Exp Ther. 2008 Feb;324(2):664-73 23019138 - J Pharmacol Exp Ther. 2013 Jan;344(1):8-14 849066 - Arch Int Pharmacodyn Ther. 1977 Jan;225(1):77-87 11067978 - J Neurophysiol. 2000 Nov;84(5):2356-64 3039112 - J Pharmacol Exp Ther. 1987 Jul;242(1):33-9 16682964 - Br J Pharmacol. 2006 Jun;148(4):387-95 20344358 - Lancet. 1947 Aug 9;2(6467):223 16968947 - Pharmacol Rev. 2006 Sep;58(3):389-462 23197773 - J Pharmacol Exp Ther. 2013 Feb;344(2):319-28 16449088 - Am J Addict. 2006 Jan-Feb;15(1):8-14 |
References_xml | |
SSID | ssj0014463 |
Score | 2.2949898 |
Snippet | Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the... |
SourceID | pubmedcentral proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 334 |
SubjectTerms | Adamantane - analogs & derivatives Adamantane - pharmacology Animals Behavioral Pharmacology Cannabinoids - pharmacology Cannabinol - analogs & derivatives Cannabinol - pharmacology Cerebellum - drug effects Cerebellum - metabolism Cerebellum - physiology Diuretics - pharmacology Dose-Response Relationship, Drug Dronabinol - pharmacology Drug Tolerance Male Mice Nociception - drug effects Receptors, Opioid, kappa - agonists |
Title | Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27231154 https://search.proquest.com/docview/1804855972 https://pubmed.ncbi.nlm.nih.gov/PMC4959092 |
Volume | 358 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLXKsGGDeFNeMhIzm06GxnEeXpZQWiENVCIjdVc5D9PwSKKSLOBj-BA-gm_i2nEStwwSsImiOA8p5-jec6-vrxF6BsGasIPUt3w75hYFB2GBbuaWR0TqOgkJhNrr8PyNt7ygr9fuejT6blQtNXV8lny7dF3J_6AK1wBXuUr2H5DtXwoX4BzwhSMgDMe_w7j8lO1Uzb9WkC_zRq1KnMyHMo2QFwWH-LfM07Yfcygdo7X3LJ8ch_PjFzPrbZXDfZPZ-1J21JXJkGgZWpFUlqBMz3WhXKdmh3VlStFWQxvstqvT3vYBxkqvXseH27JKlXxd5Gqr-37eaSUr1FURbr7jH4byFf6xURxbcLDR2yETu-C1zr6_G8qLdTbD9vpaOnBG2gITmd-YOqaJdtzA4CIxDK7TpkJ_dwSESkcAkQece2egG-02j2rQovqseEF8IlsO0cEj9nWK3dAVdJWAIZMWdLHuS4hkKO3odlHwvecHX5N9pvXzl4Uvh1W4hqyJbqDrGj08a8l1E42y4hY6WbVIfj3FkYHaKT7BKwPj26jqWYTrEgPCuGMg1gzEpcAmAzHwAh8wUD7L8c8fmn1Ysw_nBTbYhyX77qCLV_MoXFp6Dw-rAulXWwmEpIS5vk1TQX1wICz1WMLACoggm7pynjylzLOTzIdQQPhB6vqAvvAIdUVMU-cuOirKIruPMKdZGjMYdxKPxjZn8P-FzQSNWew5mT1GT7ufvAEbKSe-gIpl82VjB1PZA4n5ZIzutT99U7XNXDYdRGPk78HR3yD7r--PFPlW9WGnzGVTRh788Z0P0bWB44_QUb1rssegYev4iSLSL8o9n7M |
link.rule.ids | 230,315,783,787,888,27936,27937 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tolerance+to+the+Diuretic+Effects+of+Cannabinoids+and+Cross-Tolerance+to+a+%CE%BA-Opioid+Agonist+in+THC-Treated+Mice&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.au=Chopda%2C+Girish+R&rft.au=Parge%2C+Viraj&rft.au=Thakur%2C+Ganesh+A&rft.au=Gatley%2C+S+John&rft.date=2016-08-01&rft.eissn=1521-0103&rft.volume=358&rft.issue=2&rft.spage=334&rft_id=info:doi/10.1124%2Fjpet.116.232132&rft_id=info%3Apmid%2F27231154&rft.externalDocID=27231154 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3565&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3565&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3565&client=summon |